US Stocks
US Options
Emerging Asia
GBP Cash Savings
Charts & Tools
Paper Trading
Extended Hours
Wall Street JournalBased on the provided financial report, the title of the article is: "Atrion Corporation Reports Financial Results for the Three and Six Months Ended June 30, 2024
Based on the provided financial report, the title of the article is: "Atrion Corporation Reports Financial Results for the Three and Six Months Ended June 30, 2024
Atrion Corporation, a Delaware-based company, reported its financial results for the three and six months ended June 30, 2024. The company’s revenue increased by 10.2% to $43.1 million for the six months ended June 30, 2024, compared to $39.1 million for the same period in 2023. Net income for the six months ended June 30, 2024 was $6.3 million, or $0.36 per diluted share, compared to $5.5 million, or $0.31 per diluted share, for the same period in 2023. The company’s cash and cash equivalents increased to $24.1 million as of June 30, 2024, compared to $18.5 million as of December 31, 2023. The company’s financial condition and results of operations are discussed in more detail in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of the report.
Overview
Atrion Corporation is a company that develops and manufactures products primarily for medical applications. They market components to other equipment manufacturers and sell finished devices to healthcare providers such as physicians, hospitals, and clinics. Atrion’s medical products serve the fluid delivery, cardiovascular, and ophthalmology markets, while their other products include instrumentation and disposables used in various industries.
Atrion’s business strategy is to provide healthcare providers with the tools they need to improve patient care. They focus on customer needs, expand existing product lines, develop new products, invest in growth while controlling costs, and maintain a collaborative entrepreneurial culture.
For the three months ended June 30, 2024, Atrion reported revenues of $48.8 million, up 11% from the prior year period, operating income of $0.5 million, down 93%, and net income of $0.4 million, down 94%. The decline in profitability was primarily due to $5.0 million in expenses related to a pending merger with Nordson Corporation.
Results for the three months ended June 30, 2024
| Metric | Q2 2024 | Q2 2023 | Change |
|---|---|---|---|
| Revenues | $48.8 million | $43.8 million | +11.3% |
| Net Income | $0.4 million | $6.6 million | -94% |
| Earnings per Share (Basic) | $0.23 | $3.73 | -93.8% |
| Earnings per Share (Diluted) | $0.23 | $3.73 | -93.8% |
Revenues increased across Fluid Delivery, Cardiovascular, and Other product lines, but declined in Ophthalmology. Cost of goods sold rose 23.9% due to higher manufacturing costs, leading to a decrease in gross profit margin from 39.4% to 32.5%. Operating expenses increased $5.4 million, primarily from merger-related legal and advisory fees, resulting in a 92.8% decline in operating income.
Results for the six months ended June 30, 2024
| Metric | H1 2024 | H1 2023 | Change |
|---|---|---|---|
| Revenues | $96.1 million | $83.8 million | +14.6% |
| Net Income | $3.2 million | $10.0 million | -68% |
| Earnings per Share (Basic) | $1.81 | $5.71 | -68.3% |
| Earnings per Share (Diluted) | $1.81 | $5.70 | -68.2% |
For the first six months of 2024, revenues increased across all major product lines except Ophthalmology. However, cost of goods sold rose 24.2% due to higher manufacturing costs and a $2.3 million inventory write-off, leading to a decline in gross profit margin from 38.6% to 29.3%. Operating expenses increased $4.0 million, primarily from merger-related costs, resulting in a 69.0% decrease in operating income.
Liquidity and Capital Resources
Atrion has a $25 million revolving credit facility and $23.2 million in cash, cash equivalents, and investments as of June 30, 2024. Cash flows from operations were $22.5 million in the first half of 2024, up from $3.7 million in the prior year period. The company used cash for dividends, capital expenditures, and investments, while generating cash from investment maturities and sales.
Atrion believes its current cash, cash flows, and available credit will be sufficient to fund its cash requirements for the foreseeable future. The company also believes it has the financial strength to access equity or debt financing if needed.
Outlook and Risks
Atrion faces ongoing uncertainties related to the COVID-19 pandemic, including potential disruptions to the global economy, supply chains, and healthcare systems. The company will continue to monitor the situation and seek to mitigate any adverse impacts.
The company also cautions that forward-looking statements in this report are subject to various risks and uncertainties, including the effects of the pending merger, competition, regulatory changes, and other factors that could cause actual results to differ materially from expectations.